Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Odyssey Group Intl Inc (OP: ODYY ) 0.0436 UNCHANGED Streaming Delayed Price Updated: 10:39 AM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Odyssey Group Intl Inc < Previous 1 2 3 Next > Researchers Develop AI Tool That Scans Retina, Detects Heart Disease in One Minute October 17, 2022 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate October 14, 2022 Via Investor Brand Network BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Formation of Subsidiary Focused on Treating Neurological Disorders October 11, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Helmets Will Not Protect Individuals Against Concussions, Expert Says October 10, 2022 Via Investor Brand Network New Study Finds Hypertension Accelerates Bone Aging September 19, 2022 Via Investor Brand Network Ways to Prevent a Child from Choking August 31, 2022 Via Investor Brand Network Research to Examine Potential Link Between Concussions, Long COVID August 16, 2022 Via Investor Brand Network Exposures COVID-19 Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol October 10, 2022 Via Investor Brand Network BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program October 06, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated October 06, 2022 Via Investor Brand Network Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial October 04, 2022 Via Investor Brand Network InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Dissolves Sports Board, Releases Statement on Drug-Development Program October 03, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002 September 28, 2022 Via Investor Brand Network Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs September 28, 2022 Via Investor Brand Network NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50% September 27, 2022 Via Investor Brand Network Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses September 26, 2022 Via Investor Brand Network BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002 September 22, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial September 13, 2022 Via Investor Brand Network Study Finds That Using Headgear May Reduce Concussion Risk in Lacrosse Players September 09, 2022 Via Investor Brand Network Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage September 07, 2022 Via Investor Brand Network BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article August 29, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion August 26, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product August 25, 2022 Via Investor Brand Network Report Details Most Prevalent Symptoms of Six Cardiovascular Illnesses August 22, 2022 Via Investor Brand Network Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate August 22, 2022 Via Investor Brand Network BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial August 18, 2022 Via Investor Brand Network BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast August 16, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview August 11, 2022 Via Investor Brand Network Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy August 11, 2022 Via Investor Brand Network Topics Animal Testing Exposures Animal Testing BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial August 10, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.